IL205831A0 - Kinesin inhibitors as cancer therapeutics - Google Patents

Kinesin inhibitors as cancer therapeutics

Info

Publication number
IL205831A0
IL205831A0 IL205831A IL20583110A IL205831A0 IL 205831 A0 IL205831 A0 IL 205831A0 IL 205831 A IL205831 A IL 205831A IL 20583110 A IL20583110 A IL 20583110A IL 205831 A0 IL205831 A0 IL 205831A0
Authority
IL
Israel
Prior art keywords
cancer therapeutics
kinesin inhibitors
kinesin
inhibitors
therapeutics
Prior art date
Application number
IL205831A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL205831(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL205831A0 publication Critical patent/IL205831A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL205831A 2007-12-14 2010-05-17 Kinesin inhibitors as cancer therapeutics IL205831A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14
PCT/EP2008/067412 WO2009077448A1 (en) 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics

Publications (1)

Publication Number Publication Date
IL205831A0 true IL205831A0 (en) 2010-11-30

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205831A IL205831A0 (en) 2007-12-14 2010-05-17 Kinesin inhibitors as cancer therapeutics

Country Status (30)

Country Link
US (2) US8252832B2 (enExample)
EP (1) EP2229170B1 (enExample)
JP (1) JP5501976B2 (enExample)
KR (1) KR20100098394A (enExample)
CN (1) CN101939005B (enExample)
AR (1) AR069676A1 (enExample)
AU (1) AU2008337570B2 (enExample)
BR (1) BRPI0821248A2 (enExample)
CA (1) CA2708822A1 (enExample)
CL (1) CL2008003707A1 (enExample)
CO (1) CO6290651A2 (enExample)
CR (1) CR11412A (enExample)
DO (1) DOP2010000175A (enExample)
EA (1) EA018014B1 (enExample)
EC (1) ECSP10010248A (enExample)
ES (1) ES2459442T3 (enExample)
GE (1) GEP20125647B (enExample)
GT (1) GT201000172A (enExample)
IL (1) IL205831A0 (enExample)
MA (1) MA31872B1 (enExample)
MY (1) MY150214A (enExample)
NI (1) NI201000091A (enExample)
NZ (1) NZ585142A (enExample)
PA (1) PA8807801A1 (enExample)
PE (1) PE20091451A1 (enExample)
SM (1) SMP201000095B (enExample)
TN (1) TN2010000204A1 (enExample)
TW (1) TW200930704A (enExample)
UY (1) UY31532A1 (enExample)
WO (1) WO2009077448A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc)
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552510A (en) * 2004-06-18 2010-12-24 Novartis Vaccines & Diagnostic N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
MX2009007260A (es) 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).

Also Published As

Publication number Publication date
US8252832B2 (en) 2012-08-28
EA201000900A1 (ru) 2011-02-28
TW200930704A (en) 2009-07-16
EP2229170B1 (en) 2014-01-22
CL2008003707A1 (es) 2009-06-05
UY31532A1 (es) 2009-08-03
BRPI0821248A2 (pt) 2015-06-16
KR20100098394A (ko) 2010-09-06
PE20091451A1 (es) 2009-10-19
PA8807801A1 (es) 2009-07-23
CA2708822A1 (en) 2009-06-25
WO2009077448A1 (en) 2009-06-25
CR11412A (es) 2010-06-30
EP2229170A1 (en) 2010-09-22
JP5501976B2 (ja) 2014-05-28
NI201000091A (es) 2011-03-15
GT201000172A (es) 2012-04-30
SMAP201000095A (it) 2010-09-10
CN101939005A (zh) 2011-01-05
US20090239922A1 (en) 2009-09-24
ECSP10010248A (es) 2010-07-30
CN101939005B (zh) 2015-12-16
US20130012560A1 (en) 2013-01-10
JP2011506402A (ja) 2011-03-03
ES2459442T3 (es) 2014-05-09
TN2010000204A1 (en) 2011-11-11
MA31872B1 (fr) 2010-11-01
DOP2010000175A (es) 2010-06-30
AU2008337570B2 (en) 2012-04-05
CO6290651A2 (es) 2011-06-20
SMP201000095B (it) 2011-09-09
AU2008337570A1 (en) 2009-06-25
EA018014B1 (ru) 2013-04-30
MY150214A (en) 2013-12-13
US8664256B2 (en) 2014-03-04
AR069676A1 (es) 2010-02-10
NZ585142A (en) 2012-03-30
GEP20125647B (en) 2012-09-25

Similar Documents

Publication Publication Date Title
IL205831A0 (en) Kinesin inhibitors as cancer therapeutics
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
ZA201008808B (en) Novel phenylpyrazinones as kinase inhibitors
ZA201000829B (en) Oxadiazole- and oxazole-substituted benzamidazole-and indole-derivatives as dgat1 inhibitors
IL200596A0 (en) Tetrahydroisoquinolines as tumour growth inhibitors
IL211018A0 (en) Novel inhibitors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA201005248B (en) 4-pyridinone compounds and their use for cancer
GB0719997D0 (en) Portease Inhibition
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
GB0901898D0 (en) Dual calpain-ros inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
GB0724962D0 (en) Scale inhibition
GB201114396D0 (en) Location of basesation
GB0901900D0 (en) Dual calpain-ros inhibitors
HK1143531A (en) Kinesin inhibitors as cancer therapeutics
GB0714941D0 (en) Inhibitors
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0707632D0 (en) Novel inhibitors
GB0707488D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors
GB0707498D0 (en) Novel inhibitors
GB0707497D0 (en) Novel inhibitors
GB0707495D0 (en) Novel inhibitors